EpiCept intends to use the net proceeds it receives to meet its working capital needs and general corporate purposes through July 2008 and to pay certain fees owed to Hercules Technology Growth Capital.
Rodman & Renshaw, a subsidiary of Rodman & Renshaw Capital Group, acted as the exclusive placement agent for the offering.